

Faculty Disclosures

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, course directors, planners, moderators, faculty, and all others in control of the educational content of the continuing education activity must disclose all financial relationships with ineligible companies that they may have had within the past 24 months. If an individual refuses to disclose financial relationships, they will be disqualified from being a part of the planning and implementation of the activity. Owners and/or employees of an ineligible company with business lines or products relating to the content of the activity will not be permitted to participate in the planning or execution of any accredited program. All listed relevant financial relationships with ineligible companies for individuals in control of content have been mitigated.

Name	Role in Activity	Ineligible Company	Nature of Relevant Financial Relationship
Maria Abreu, MD (Cedars-Sinai)	Speaker, Moderator	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Mazer Ally, MD (Scripps)	Speaker, Planning Committee	<ul style="list-style-type: none"> AbbVie Lilly, Sanare 	<ul style="list-style-type: none"> Speaker Consultant
Tina Aswani-Omprakash, MPH (South Asian IBD Alliance)	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Edward Barnes, MD, MPH (UNC)	Speaker	<ul style="list-style-type: none"> BMS, Eli Lilly AbbVie, Target RWE 	<ul style="list-style-type: none"> Advisory Board Consultant
Lori Beeken, MS, RDN (Scripps)	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Willem Bemelman, MD, PhD (Amsterdam University)	Speaker, Moderator	<ul style="list-style-type: none"> Janssen, Medtronic, Galapagos 	<ul style="list-style-type: none"> Speaker
Brigid Boland, MD (UCSD)	Planning Committee, Speaker	<ul style="list-style-type: none"> Celltrion, BMS, AbbVie Merck Mirador 	<ul style="list-style-type: none"> Consultant Consultant, Research Grant Research Grant
Michael Bollong, PhD (Scripps Research)	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Arnab Chatterjee, PhD (Scripps Research)	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Angelina Collins, MSN, ANP-BC (UCSD)	Planning Committee, Speaker	<ul style="list-style-type: none"> AbbVie, Janssen Eli Lilly Takeda 	<ul style="list-style-type: none"> Speaker, Consultant, Advisory Board Speaker, Advisory Board Speaker, Consultant
Andre D'Hoore, MD, PhD (IBD Leuven Belgium)	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Marla Dubinsky, MD (Mount Sinai)	Speaker, Moderator	<ul style="list-style-type: none"> Abbvie, Abivax, Astra Zeneca, BMC, Celltrion, Genentech, Johnson and Johnson, Janssen, Lilly, Merck, Pfizer, Prometheus Biosciences, Sanofi, Spyre, Takeda 	<ul style="list-style-type: none"> Consultant, Advisor
Melissa Ferarri, PA-C, MPAS (Scripps)	Planning Committee, Speaker	<ul style="list-style-type: none"> AbbVie, Janssen Eli Lilly, Pfizer 	<ul style="list-style-type: none"> Speaker Advisory Board
Phillip Fleshner, MD (Cedars-Sinai)	Speaker, Moderator	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Madison Folsom, PA (Scripps)	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Pradipta Ghosh, MD (UCSD)	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A

Name	Role in Activity	Ineligible Company	Nature of Relevant Financial Relationship
Howard Hang, PhD (Scripps Research)	Moderator	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Jeannie Huang, MD, MPH (Rady Children's Hospital)	Speaker, Moderator	<ul style="list-style-type: none"> AbbVie, Takeda, Janssen, Lilly 	<ul style="list-style-type: none"> Research Funding
Gauree Gupta Konijeti, MD, MPH	Planning Committee, Speaker, Moderator	<ul style="list-style-type: none"> AbbVie Takeda Lilly Pfizer 	<ul style="list-style-type: none"> Advisory Board, Consultant Speakers Bureau Consultant, Speakers Bureau Advisory Board
Paulo Kotze, MD, PhD (Catholic University of Parana Curitiba Brazil)	Speaker, Moderator	<ul style="list-style-type: none"> Janssen, AbbVie, Pfizer, Takeda Pfizer, Takeda 	<ul style="list-style-type: none"> Speaker, Advisory Board Research Grant Funding
Amy Lightner, MD (Scripps, Scripps Research)	Planning Committee, Speaker, Moderator	<ul style="list-style-type: none"> Direct Biologics Boomerang Medical Astellas, Pfizer 	<ul style="list-style-type: none"> Employment CMO Consultant CMO Consultant
James Marion, MD (Mount Sinai)	Speaker, Moderator	<ul style="list-style-type: none"> Janssen 	<ul style="list-style-type: none"> Advisory Board
Gil Melmed, MD (Cedars-Sinai)	Speaker	<ul style="list-style-type: none"> Abbvie, Arena, Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Janssen, Gilead, Genentech, Pfizer, Samsung Bioepis, Takeda, Shionogi, Prometheus Labs, Techlab, Fresenius Kabi, Amgen Pfizer 	<ul style="list-style-type: none"> Consultant Research Grant Funding
Alan Moss, MD (Boston University)	Speaker, Moderator	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Taraneh Paravar, MD (UCSD)	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
David Rubin, MD (University of Chicago)	Speaker, Moderator	<ul style="list-style-type: none"> Takeda AbbVie, Abivax, SA, Altrubio, Avalo Therapeutics, Bausch Health, BMS, Buhlmann Diagnostics, Celltrion, ClostraBio, Connect BioPharma, Douglas Pharmaceuticals, Eli Lilly, Foresee, Genentech, Image Analysis Group, InDex Pharmaceuticals, Iterative Health, Janssen, Odyssey Therapeutics, Pfizer, Sanofi, Takeda, Throne, Vedanta Crohn's & Colitis Foundation Cornerstones Health 	<ul style="list-style-type: none"> Grant Support Consultant Board of Trustees Board of Directors
Peter Schultz, MD (Scripps Research)	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Siddharth Singh, MD (UCSD)	Planning Committee, Speaker, Moderator	<ul style="list-style-type: none"> Pfizer 	<ul style="list-style-type: none"> Research Grant Funding
Preetika Sinh, MD (UCSD)	Speaker	<ul style="list-style-type: none"> Takeda Lilly, Takeda 	<ul style="list-style-type: none"> Research Grant Funding Speakers Bureau

Name	Role in Activity	Ineligible Company	Nature of Relevant Financial Relationship
Scott Snapper, MD, PhD (Boston Children’s Hospital)	Speaker	<ul style="list-style-type: none"> Pfizer, Merck, Duallyx, Spyre Therapeutics, Biologic Design, Trex Bio Sonoma Biotherapeutics Zag Bio, Ignite 	<ul style="list-style-type: none"> Advisory Board Advisory Board, Stock Consultant
Antonino Spinelli, MD, PhD (Humanitas Milan Italy)	Speaker, Moderator	<ul style="list-style-type: none"> Takeda, Johnson & Johnson, Sofar 	<ul style="list-style-type: none"> Consultant
Phil Tozer, MBBS (St. Mark’s Hospital London)	Speaker	<ul style="list-style-type: none"> Takeda, Ferring 	<ul style="list-style-type: none"> Speaker, Advisory Board
Janindra Warusavitarne, B Med, FRACS, PhD (St. Mark’s Hospital London)	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
CME Committee	CE approval, all final decision-making on activities	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Scripps Conference Services & CME	Plan, manage, implement, and reconcile CE activities	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A

Glossary of Terms

Ineligible Company

An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. For specific examples of ineligible companies visit www.accme.org/standards.

Financial Relationships

Financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor, research funding, royalties or patent beneficiary, executive role, and ownership interest. Individual stocks and stock options should be disclosed.